Introduction EdiGene is a company that focuses on creating and utilizing genome editing technology for the betterment of human health. This technology allows for precise modifications to be made to genetic information within human cells, such as the removal or addition of genes, as well as targeted changes to specific genes. The company's goal is to provide top-quality products and services to patients, the pharmaceutical industry, and scientific researchers by utilizing the most advanced genome editing technology available. EdiGene also develops human therapeutic products by applying genome editing technology, with the aim of treating diseases at the molecular level to make gene therapy safer and more effective. |
Disease Domain | Count |
---|---|
Hemic and Lymphatic Diseases | 5 |
Immune System Diseases | 3 |
Neoplasms | 3 |
Nervous System Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
AAV based gene therapy | 2 |
Universal CAR-T | 2 |
CAR-T | 1 |
CRISPR/Cas | 1 |
Gene editing | 1 |
Top 5 Target | Count |
---|---|
CD19(B-lymphocyte antigen CD19) | 3 |
usherin | 1 |
BCL11A(B-cell lymphoma/leukemia 11A) | 1 |
Target |
Mechanism CD19 modulators [+2] |
Active Org. EdiGene Inc.Startup |
Originator Org. EdiGene Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD19 modulators [+1] |
Active Org. EdiGene Inc.Startup |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism BCL11A modulators [+1] |
Active Org. |
Originator Org. EdiGene Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date24 Jul 2024 |
Sponsor / Collaborator EdiGene Inc.Startup |
Start Date01 Jul 2024 |
Sponsor / Collaborator |
Start Date06 Sep 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
TCR reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T cell(Chinese PLA General Hospital) ( CD19 ) | Pre B-cell acute lymphoblastic leukemia More | Phase 2 Clinical |
ATHENA CAR-T(EdiGene) ( CD19 ) | B-Cell Lymphoma More | Phase 2 Clinical |
ET-01 (Edigene) ( BCL11A ) | Transfusion-dependent Beta Thalassemia More | Phase 1 |
ET-02 ( CD19 ) | B-Cell Malignant Neoplasm More | Clinical |
Alpha-1 anti trypsin related liver disease (Boyajin) | Alpha 1-Antitrypsin Deficiency More | Preclinical |